Lasers in the management of alopecia: a review of established therapies and advances in treatment.

Lasers Med Sci

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, 1600 NW 10th Ave, 33136, Miami, FL, USA.

Published: April 2024

Alopecia, also known as hair loss, is a highly prevalent condition affecting millions of men and women in the United States and worldwide, making it one of the most common complaints by patients presenting to a dermatologist. The symptomology on the presentation of alopecia can be highly variable, ranging from diffuse thinning of hair, discrete and localized patches completely absent of hair, or noticing significant shedding when brushing and showering. Although alopecia does not have a direct negative health impact on patients, it is nonetheless a debilitating disease as it can profoundly impact an individual's self-image and psychosocial well-being. There are multiple treatment options available to patients with alopecia, and they are typically tailored to the patient's needs and preferences. The most common of these is the Food and Drug Administration-approved drugs for alopecia, minoxidil, and finasteride. However, both of these are known to be partially efficacious for all patients, so clinicians often use different modalities in conjunction with them, in particular laser-based therapies. This review article will provide a comprehensive assessment of lasers and other light therapies that may be used to manage the two most common types of alopecia: androgenetic alopecia and alopecia areata.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11023987PMC
http://dx.doi.org/10.1007/s10103-024-04054-7DOI Listing

Publication Analysis

Top Keywords

alopecia
9
lasers management
4
management alopecia
4
alopecia review
4
review established
4
established therapies
4
therapies advances
4
advances treatment
4
treatment alopecia
4
alopecia hair
4

Similar Publications

Clinical, Laboratory, and Trichoscopic Features of Pediatric Androgenetic Alopecia.

Cutis

December 2024

Drs. Lu, Du, Zhao, and Fan and Lingbo Bi, Chaofan Wang, and Yunbu Ding are from the Department of Dermatology, The First Affiliated Hospital of Nanjing Medical University, China. Yige Fan is from the Mayo Clinic, Rochester, Minnesota.

Article Synopsis
  • The study reviewed 133 pediatric patients over 14 years to understand the prevalence and effects of androgenetic alopecia (AGA), with symptoms appearing as early as age 10.
  • Factors such as BMI, family history, comorbidities, and hair loss patterns were examined, revealing differences in trichoscopic outcomes between sexes and age groups.
  • The research emphasizes the need for personalized treatment plans for AGA in children, suggesting the use of topical minoxidil while ensuring close monitoring and encouraging adherence to medication and follow-ups for better results.
View Article and Find Full Text PDF

Introduction: Patients with moderate-to-severe atopic dermatitis (AD), a body surface area (BSA) of ≤ 40%, and an itch numerical rating scale (NRS) score of ≥ 7 ("BARI itch dominant") have been characterized as an important group to consider for the oral janus kinase (JAK) 1/2 inhibitor baricitinib (BARI). Herein we aim to evaluate quality of life (QoL) and functioning outcomes in adult patients with BSA ≤ 40% and itch NRS ≥ 7 at baseline (BL) who received BARI 4 mg in the topical corticosteroid (TCS) combination trial BREEZE-AD7.

Materials: BREEZE-AD7 was a randomized, double-blind, placebo-controlled, parallel-group outpatient study involving adult patients with moderate-to-severe AD who received once-daily placebo or 2-mg or 4-mg BARI in combination with TCS for 16 weeks.

View Article and Find Full Text PDF

Background: Intralesional (IL) steroids are the first-line treatment option for localized alopecia areata (AA). The present study aimed to compare the efficacy of topical calcipotriol with IL triamcinolone acetonide versus IL triamcinolone acetonide alone in AA.

Methods: This randomized single-blinded clinical trial was conducted in a dermatology outpatient department.

View Article and Find Full Text PDF

Background: Alopecia X (AX) is a common noninflammatory alopecic condition of Pomeranian dogs with an unknown cause. While a genetic aetiology is suspected, no current tests can predict the development of this disorder or confirm the aetiology. Therefore, identifying potential risk indicators for the development of AX would be of value in this breed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!